-
货号
KDC36901
-
描述
PRINCIPLE OF THE ASSAY This assay employs the quantitative competitive enzyme immunoassay technique. Recombinant human IL6R antigen has been pre-coated onto a microplate. Standards or samples are premixed with biotin-labeled antibody and then pipetted into the wells. Tocilizumab in the sample competitively binds to the pre-coated protein with biotin-labeled Tocilizumab. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in inversely proportion to the amount of Tocilizumab bound in the initial step. The color development is stopped and the intensity of the color is measured.
-
应用
Used for the quantitative determination of Tocilizumab concentration in serum and plasma. -
检测方法
Colorimetric -
样本类型
Plasma, Serum -
实验类型
Quantitative -
检测范围
156.3 ng/mL—10000 ng/mL -
精准度
Intra-Assay Precision (Precision within an assay): <10%
Inter-Assay Precision (Precision between assays): <15%
Intra-Assay Precision
Inter-Assay Precision
Sample
1
2
3
1
2
3
n
16
16
16
24
24
24
Mean (ng/mL)
4802.5
1358.4
255.8
4927.2
1288.7
261.6
Standard deviation
367
115
26
557
170
31
CV (%)
7.7
8.5
10.0
11.3
13.2
11.9
-
回收率
80-120% -
运输
2-8 ℃ -
稳定性和存储
The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 20% prior to the expiration date under appropriate storage condition. -
别名
Atlizumab, MRA / R-1569 / RHPM-1 / RO-4877533, CAS: 375823-41-9
-
背景
Tocilizumab is a humanized IgG1 monoclonal antibody to the IL-6 receptor that is used largely as therapy of refractory rheumatoid arthritis and other inflammatory arthritides. Tocilizumab blocks the action of IL-6, which is a key proinflammatory cytokine that mediates a wide spectrum of biologic activities including activation of T cells, differentiation of B cells, induction of acute phase reactants, proliferation of fibroblasts, and damage to cartilage and joints. IL-6 levels are elevated in patients with active rheumatoid arthritis. In controlled trials and open label studies, tocilizumab therapy led to improvements in symptoms and laboratory abnormalities associated with several forms of inflammatory arthritis. Tocilizumab was approved for use in the United States in 2010 and current indications include rheumatoid arthritis, giant cell arteritis and both the polyarticular and systemic forms of juvenile idiopathic arthritis (formerly juvenile rheumatoid arthritis). Tocilizumab is considered a disease modifying antirheumatic drug (DMARD) and improves signs and symptoms of disease and decreases cartilage and tissue destruction.
